Clinical Trials Browser

Interventional × devimistat × Thoracic × Clear all

NCT05733000 2023-03-10

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

Phase 2 Recruiting

GastrointestinalGenitourinaryGynecologicThoracic

Adenocarcinoma of Lung, Carcinoma, Transitional Cell, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT03370159 2018-08-01

CPI-613 and Docetaxel in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer

Phase 1/2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT01931787 2018-07-03

CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

Phase 1 Completed

Small Cell Lung Carcinoma

NCT01832857 2016-12-29

Phase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer Patients

Phase 2 Terminated

BreastGastrointestinalThoracic

Breast Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms